Landmark PALISADE trial of AR101 published in New England Journal of Medicine
Aimmune Therapeutics announced the NEJM has published the results of the landmark phase 3 PALISADE clinical trial of AR101, Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. November 18, 2018